Figure 2.

IL4I1 favors melanoma progression and metastasis formation with no direct effect on tumor cell proliferation and angiogenesis. (A–E) Melanoma progression in Ret (black line, n = 28) or RetIL4I1KO (gray line, n = 32) mice was evaluated once a week over a 3-mo period. Time courses of primary tumor (A), facial (B) or dorsal (C) metastasis onset. Frequency of 3-mo old mice with distant metastasis (D) or vitiligo (E) are shown. Mantel-Cox test (A–C). (F) Illustration and quantification of the CD34 vessel staining in primary tumors of 3-mo old Ret or RetIL4I1KO mice. Scale bar, 100 µm. (G) Growth comparison of B16-F10 cells seeded in E-plates wells with or without recombinant IL4I1. (H) Proportion of KI67⁺ cells among CD45⁻ cells within the primary tumors of 3-mo old Ret and RetIL4I1KO mice. Data were pooled from at least three experiments. *p < 0.05.